<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680105</url>
  </required_header>
  <id_info>
    <org_study_id>RPI003</org_study_id>
    <nct_id>NCT03680105</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of RJX Drug Product in Healthy Participants</brief_title>
  <official_title>A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ERT: Clinical Trial Technology Solutions</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Reven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Designed as a single center, two-part, double-blind, placebo-controlled, randomized study to
      assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RJX in
      healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is designed as a Single Ascending Dose (SAD) escalation study with 6 cohorts.
      Participants will undertake a screening visit between Day -21 and Day -1 to determine
      eligibility in the study. Those participants that meet the eligibility criteria will be
      admitted to the study site on the day prior to dosing (Day -1). Participants will receive a
      single dose of investigational product via IV infusion on Day 1. The first cohort will
      include the initial dosing of a sentinel group. The remaining participants in Cohort 1 will
      be dosed if, in the opinion of the investigator or delegate, there are no significant safety
      concerns identified in the sentinel participants within the first 24 hours after
      administration of the dose. Participants will be confined to the study site from Day -1 to
      Day 2 (24 hours post dose) and then required to return to the study site on Day 5 for a final
      follow up visit. Safety and PK assessments will be performed at selected time points
      throughout the study.

      Part 2 is designed as a Multiple Ascending Dose (MAD) escalation study with 3 cohorts. The
      MAD arm of the study will commence in parallel with Cohort 6 of Part 1 following completion
      and review of safety and PK findings for Cohorts 1, 2, 3, 4, and 5 in Part 1. Participants
      will undertake a screening visit between Day -21 and Day -1 to determine eligibility in the
      study. Those participants that meet the eligibility criteria will be admitted to the study
      site on the day prior to dosing (Day -1). Participants will be randomly assigned to receive 1
      of 3 proposed doses of investigational product via IV infusion every day for 7
      days.Participants will be confined to the study site from Day -1 to Day 8 (24 hours post the
      final dose on Day 7) and then return to the study site on Day 12 for a final follow up visit.
      Safety and PK assessments will be performed at selected time points throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related Adverse Events (TEAE) Reporting of RJX</measure>
    <time_frame>Up to Day 5 for Part 1 and Up to Day 12 for Part 2</time_frame>
    <description>Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).</measure>
    <time_frame>Up to Day 2 for Part 1 and Up to Day 8 for Part 2</time_frame>
    <description>Number of participants with abnormal and clinically significant findings based on ECG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of RJX as Assessed by Neurological Examinations.</measure>
    <time_frame>Up to Day 5 for Part 1 and Up to Day 12 for Part 2</time_frame>
    <description>Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments.</description>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Part 1; Cohort 1; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; Cohort 2; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; Cohort 3; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; Cohort 4; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; Cohort 5; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1; Cohort 6; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; Cohort 1; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; Cohort 2; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2; Cohort 3; RJX or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RJX</intervention_name>
    <description>RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).</description>
    <arm_group_label>Part 1; Cohort 1; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 2; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 3; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 4; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 5; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 6; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 2; Cohort 1; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 2; Cohort 2; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 2; Cohort 3; RJX or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.</description>
    <arm_group_label>Part 1; Cohort 1; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 2; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 3; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 4; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 5; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 1; Cohort 6; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 2; Cohort 1; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 2; Cohort 2; RJX or Placebo</arm_group_label>
    <arm_group_label>Part 2; Cohort 3; RJX or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female participants aged 18 to 50 years inclusive (Cohort 1 to Cohort
             5) or 51 to 70 years inclusive (Cohort 6 only),at the time of screening;

          2. Have a body mass index of 18 kg/m2 to 35 kg/m2, inclusive, at screening. In addition,
             weight cannot exceed 132 kg;

          3. Have negative screening assessment for viral hepatitis (hepatitis B or hepatitis C)
             and human immunodeficiency virus;

          4. Have negative routine urine drug screen and negative alcohol breath test at screening
             and Day -1;

          5. A female participant is eligible to participate if she is not pregnant,not
             breastfeeding, and at least 1 of the following conditions applies:

               1. Not of childbearing potential, defined as surgically sterile (documented
                  hysterectomy, bilateral salpingectomy, tubal ligation or bilateral oophorectomy)
                  or postmenopausal (no menses for 12 months without an alternative medical cause.
                  A high follicle stimulating hormone (FSH) level in the postmenopausal range may
                  be used to confirm a postmenopausal state in women not using hormonal
                  contraception or hormonal replacement therapy; however, in the absence of 12
                  months of amenorrhea, a single FSH measurement is insufficient);

               2. Of childbearing potential and agrees to use 2 highly effective methods of
                  contraception consistently during the treatment period and for at least 60 days
                  after the last dose of investigational product;

          6. A male participant with a female partner of childbearing potential is eligible to
             participate if he agrees to use acceptable contraception during the treatment period
             and for at least 60 days after the last dose of investigational product and refrains
             from donating sperm during this period;

          7. Clinical laboratory test results within normal reference range for the population or
             investigator site, or any results that are judged to be not clinically significant by
             the investigator;

          8. Venous access sufficient to allow for blood sampling per the protocol;

          9. Reliable and willing to make themselves available for the duration of the study and
             are willing to follow study procedures;

         10. Given written informed consent prior to any study procedures being performed

        Exclusion Criteria:

          1. Have a history of clinically relevant cardiovascular disease, cancer, respiratory,
             hepatic, renal, gastrointestinal, endocrine (diabetes), hematological, or neurological
             disorders. Cohort 6 only - elderly participants with well controlled
             hypercholesterolemia on a stable dose of statin therapy or well controlled
             hypertension on a stable dose of antihypertensive medication(s), excluding diuretics,
             are allowed in Cohort 6 per the clinical judgment of the investigator.

          2. Have impaired renal function (defined as estimated glomerular filtration rate &lt;90
             cc/min/1.73m2 Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) creatinine
             equation at screening);

          3. Have a hsCRP above 1.25 Ã— upper limit of normal;

          4. Have a clinically significant abnormality in the 12-lead electrocardiogram (ECG) or
             prolongation of corrected QT interval by Fredericia (QTcF) &gt;440 ms in males and &gt;450
             ms in females;

          5. Have a supine systolic blood pressure (BP) greater than 140 mm Hg or a diastolic BP
             greater than 90 mm Hg. Up to 2 additional measurements may be undertaken after an
             appropriate resting interval at screening to confirm eligibility;

          6. Are currently enrolled in a clinical trial involving an investigational product, or
             are concurrently enrolled in any other type of medical research judged not to be
             scientifically or medically compatible with this study;

          7. Have received an investigational product within the last 3 months;

          8. Have suspected allergies to RJX, related compounds, or any components of the
             formulation, or history of significant atopy;

          9. Regularly use known drugs of abuse and/or show positive findings on drug screening or
             Day -1;

         10. Are women who are pregnant, intend to become pregnant, or are lactating;

         11. Participants will be excluded for using any of the following medication:

               -  aspirin, multivitamins/vitamins or mineral preparations within 14 days prior to
                  investigational product administration or 24 hours post the last infusion;

               -  prescription, herbal or over the counter medications within 14 days of
                  investigational product administration, with the exception of:

                    -  simple analgesics such as paracetamol, excluding aspirin

                    -  oral non-steroidal anti-inflammatory drugs

                    -  thyroid treatment, estrogen replacement therapy

                    -  hormonal contraception

                    -  Statins and anti-hypertensives are permitted for elderly participants in
                       Cohort 6 (Part 1) - see inclusion criteria #1

         12. Have donated blood of more than 500 mL within 4 weeks prior to study enrollment;

         13. Have an average weekly alcohol intake that exceeds 21 units per week (males up to age
             65) and 14 units per week (males over 65 and females) or are unwilling to stop alcohol
             consumption for 24 hours prior to study site admission (1 unit = 12 oz or 360 mL of
             beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits). Participants must
             have a of negative alcohol breath test at Day -1 and no evidence of alcohol abuse in
             the previous 12 months, defined as &gt; 21 weekly units for males up to age 65 and &gt; 14
             weekly units for males over 65 and females;

         14. Have smoked cigarettes in the last 90 days (including occasional smokers who have
             smoked more than 5 cigarettes per month within the last 90 days);

         15. In the opinion of the investigator or sponsor, are unsuitable for inclusion in the
             study;

         16. Are investigator site personnel directly affiliated with this study and their
             immediate families. Immediate family is defined as a spouse, parent, child or sibling,
             whether biological or legally adopted;

         17. Are Reven employees or employees of third-party organizations involved with the study
             who require exclusion of their employees.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis A Ruff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON Early Phase Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Early Phase Services</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <results_first_submitted>March 31, 2020</results_first_submitted>
  <results_first_submitted_qc>March 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2020</results_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03680105/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants received either Rejuveinix (RJX) or saline placebo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1; Cohort 1; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1; Cohort 2; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1; Cohort 3; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1; Cohort 4; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1; Cohort 5; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1; Cohort 6; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 6 received a single dose of 0.500 mL/kg RJX or matching placebo on Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 51-70 inclusive.</description>
        </group>
        <group group_id="P7">
          <title>Part 2; Cohort 1; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX or matching placebo every day for 7 days.</description>
        </group>
        <group group_id="P8">
          <title>Part 2; Cohort 2; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX or matching placebo every day for 7 days.</description>
        </group>
        <group group_id="P9">
          <title>Part 2; Cohort 3; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX or matching placebo every day for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1; Cohort 1; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1; Cohort 2; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1; Cohort 3; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1; Cohort 4; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1; Cohort 5; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1; Cohort 6; RJX or Placebo</title>
          <description>Participants in Part 1; Cohort 6 received a single dose of 0.500 mL/kg RJX or matching placebo on Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 51-70 inclusive.</description>
        </group>
        <group group_id="B7">
          <title>Part 2; Cohort 1; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX or matching placebo every day for 7 days.</description>
        </group>
        <group group_id="B8">
          <title>Part 2; Cohort 2; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX or matching placebo every day for 7 days.</description>
        </group>
        <group group_id="B9">
          <title>Part 2; Cohort 3; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX or matching placebo every day for 7 days.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="8"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment-related Adverse Events (TEAE) Reporting of RJX</title>
        <description>Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03</description>
        <time_frame>Up to Day 5 for Part 1 and Up to Day 12 for Part 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1; Placebo</title>
            <description>Participants in Part 1 received a single saline placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1; Cohort 1; RJX</title>
            <description>Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1; Cohort 2; RJX</title>
            <description>Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1; Cohort 3; RJX</title>
            <description>Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1; Cohort 4; RJX</title>
            <description>Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1; Cohort 5; RJX</title>
            <description>Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1; Cohort 6; RJX</title>
            <description>Participants in Part 1; Cohort 6 received a single dose of 0.500 mL/kg RJX Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 51-70 inclusive.</description>
          </group>
          <group group_id="O8">
            <title>Part 2; Placebo</title>
            <description>Participants in Part 2 received a dose of saline placebo every day for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Part 2; Cohort 1; RJX</title>
            <description>Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX every day for 7 days.</description>
          </group>
          <group group_id="O10">
            <title>Part 2; Cohort 2; RJX</title>
            <description>Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX every day for 7 days.</description>
          </group>
          <group group_id="O11">
            <title>Part 2; Cohort 3; RJX</title>
            <description>Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX every day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-related Adverse Events (TEAE) Reporting of RJX</title>
          <description>Number of participants with indicated AEs receiving RJX as assessed by CTCAE v4 03</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild TEAE</title>
              <category_list>
                <category>
                  <title>With TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate TEAE</title>
              <category_list>
                <category>
                  <title>With TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe TEAE</title>
              <category_list>
                <category>
                  <title>With TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related TEAE</title>
              <category_list>
                <category>
                  <title>With TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Without TEAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).</title>
        <description>Number of participants with abnormal and clinically significant findings based on ECG.</description>
        <time_frame>Up to Day 2 for Part 1 and Up to Day 8 for Part 2</time_frame>
        <population>Counts of 12-lead safety ECG interpretations across Intent to Treat (ITT) population showed no notable changes when compared to baseline for either study part.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1; Placebo</title>
            <description>Participants in Part 1 received a single saline placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1; Cohort 1; RJX</title>
            <description>Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1; Cohort 2; RJX</title>
            <description>Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1; Cohort 3; RJX</title>
            <description>Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1; Cohort 4; RJX</title>
            <description>Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1; Cohort 5; RJX</title>
            <description>Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1; Cohort 6; RJX</title>
            <description>Participants in Part 1; Cohort 6 received a single dose of 0.500 mL/kg RJX Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 51-70 inclusive.</description>
          </group>
          <group group_id="O8">
            <title>Part 2; Placebo</title>
            <description>Participants in Part 2 received a dose of saline placebo every day for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Part 2; Cohort 1; RJX</title>
            <description>Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX every day for 7 days.</description>
          </group>
          <group group_id="O10">
            <title>Part 2; Cohort 2; RJX</title>
            <description>Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX every day for 7 days.</description>
          </group>
          <group group_id="O11">
            <title>Part 2; Cohort 3; RJX</title>
            <description>Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX every day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of RJX as Assessed by Electrocardiograms (ECGs).</title>
          <description>Number of participants with abnormal and clinically significant findings based on ECG.</description>
          <population>Counts of 12-lead safety ECG interpretations across Intent to Treat (ITT) population showed no notable changes when compared to baseline for either study part.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of RJX as Assessed by Neurological Examinations.</title>
        <description>Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments.</description>
        <time_frame>Up to Day 5 for Part 1 and Up to Day 12 for Part 2</time_frame>
        <population>Analysis based on Intent to Treat (ITT) population across Part 1 and Part 2, all cohorts. Only 1 subject, one incidence, for the study; presented on Day 12, Principal Investigator considered clinically significant and a mild TEAE considered unlikely related to RJX.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1; Placebo</title>
            <description>Participants in Part 1 received a single saline placebo on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1; Cohort 1; RJX</title>
            <description>Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1; Cohort 2; RJX</title>
            <description>Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1; Cohort 3; RJX</title>
            <description>Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1; Cohort 4; RJX</title>
            <description>Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1; Cohort 5; RJX</title>
            <description>Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1; Cohort 6; RJX</title>
            <description>Participants in Part 1; Cohort 6 received a single dose of 0.500 mL/kg RJX Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 51-70 inclusive.</description>
          </group>
          <group group_id="O8">
            <title>Part 2; Placebo</title>
            <description>Participants in Part 2 received a dose of saline placebo every day for 7 days.</description>
          </group>
          <group group_id="O9">
            <title>Part 2; Cohort 1; RJX</title>
            <description>Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX every day for 7 days.</description>
          </group>
          <group group_id="O10">
            <title>Part 2; Cohort 2; RJX</title>
            <description>Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX every day for 7 days.</description>
          </group>
          <group group_id="O11">
            <title>Part 2; Cohort 3; RJX</title>
            <description>Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX every day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of RJX as Assessed by Neurological Examinations.</title>
          <description>Number of participants with clinically significant values and actual changes from baseline of continuous neurological assessments.</description>
          <population>Analysis based on Intent to Treat (ITT) population across Part 1 and Part 2, all cohorts. Only 1 subject, one incidence, for the study; presented on Day 12, Principal Investigator considered clinically significant and a mild TEAE considered unlikely related to RJX.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1 (SAD): 5 Days Part 2 (MAD) 12 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1; Placebo</title>
          <description>Participants in Part 1 received a single saline placebo on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1; Cohort 1; RJX</title>
          <description>Participants in Part 1; Cohort 1 received a single 0.024 mL/kg dose of RJX on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1; Cohort 2; RJX</title>
          <description>Participants in Part 1; Cohort 2 received a single 0.076 mL/kg dose of RJX on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1; Cohort 3; RJX</title>
          <description>Participants in Part 1; Cohort 3 received a single 0.240 mL/kg dose of RJX on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1; Cohort 4; RJX</title>
          <description>Participants in Part 1; Cohort 4 received a single 0.500 mL/kg dose of RJX on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1; Cohort 5; RJX</title>
          <description>Participants in Part 1; Cohort 5 received a single 0.759 mL/kg dose of RJX on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 1; Cohort 6; RJX</title>
          <description>Participants in Part 1; Cohort 6 receive a single dose of 0.500 mL/kg RJX on Day 1.
Cohort 6 subjects comprised a cohort of healthy volunteers aged 50-70 inclusive.</description>
        </group>
        <group group_id="E8">
          <title>Part 2; Placebo</title>
          <description>Participants in Part 2 received a saline placebo every day for 7 days.</description>
        </group>
        <group group_id="E9">
          <title>Part 2; Cohort 1; RJX</title>
          <description>Participants in Part 2; Cohort 1 received a dose of 0.240 mL/kg RJX every day for 7 days.</description>
        </group>
        <group group_id="E10">
          <title>Part 2; Cohort 2; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 2 received a dose of 0.500 mL/kg RJX every day for 7 days.</description>
        </group>
        <group group_id="E11">
          <title>Part 2; Cohort 3; RJX or Placebo</title>
          <description>Participants in Part 2; Cohort 3 received a dose of 0.759 mL/kg RJX every day for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion Site Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infusion Site Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Systolic Decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>C-reactive Protein Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Delayed Sleep Phase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Clonus</sub_title>
                <description>Ankle clonus</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head, Global Clinical Affairs</name_or_title>
      <organization>Reven Pharmaceuticals</organization>
      <phone>13036691336</phone>
      <email>kristina.cabala@reven.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

